COSMO BIO COMPANY,LIMITED
3386・Standard Market・Wholesale Trade
Business
COSMO BIO CO., LTD. is a life science specialty trading company founded in 1983. It procures over 10 million types of research reagents and instruments from approximately 500 suppliers worldwide, supplying them to researchers at universities, public research institutions, and companies. Domestically, it operates nationwide through a distributor network, while overseas it also conducts global sales (¥1,506 million) through its US subsidiary, COSMO BIO USA, INC. The company also develops value-added businesses beyond typical trading company functions, including proprietary products (primary cultured cells, assay kits, custom peptide synthesis), contract services (drug discovery support, gut flora analysis, etc.), and protein manufacturing utilizing egg bioreactor technology.
Business Model
The company procures products from approximately 500 suppliers worldwide, adds value in the form of 'clarity, reassurance, and safety,' and wholesales them to researchers nationwide through distributors. Of net sales of ¥10,766 million, Research Reagents account for 79.5% (¥8,558 million) and instruments for 20.5% (¥2,207 million). Proprietary products and contract services, along with export sales through COSMO BIO USA, contribute to revenue diversification, and the gross profit margin has improved to 34.4%.
Company Strengths
The company handles cutting-edge products exceeding 10 million items sourced from a supplier network of approximately 500 companies worldwide. The specialized expertise required to efficiently match the vast product range with researchers' needs serves as a barrier to entry, and Research Reagents sales achieved ¥8,558 million, up 7.7% year on year.
The company operates proprietary products and contract businesses that go beyond import and sales, including primary cultured cells, Custom Peptide Synthesis & Antibody Production Service, and protein manufacturing using egg bioreactors. These have contributed to the improvement in gross profit margin (from 33.2% to 34.4%).
As of the end of the fiscal year ending December 2025, against total assets of ¥12,662 million, net assets stood at ¥9,955 million, with an equity ratio of 74.0%. Fund procurement is based fundamentally on internal funds, maintaining a sound financial structure that does not rely on interest-bearing debt. Cash and cash equivalents secured amounted to ¥2,747 million.
ENVALITH's Perspective
Performance Trend
Revenue accelerated its recovery, rising from ¥10,037 million in FY2024 to ¥10,766 million in FY2025, and to ¥3,331 million in Q1 of FY2026 (ending December 2026) (up 7.7% year on year). Operating profit, on the other hand, continues to show structural deterioration, having fallen to roughly one-third of its level over four years—from ¥1,048 million in FY2021 to ¥343 million in FY2025—and the full-year forecast for FY2026 (ending December 2026) of ¥270 million (down 21.3% year on year) shows no sign of improvement. Q1 net income attributable to owners of the parent of ¥222 million (up 4.7% year on year) was largely supported by an extraordinary gain of ¥70 million from the sale of investment securities (versus ¥28 million in the same period of the previous year), indicating that the recovery in core earnings power has not yet been achieved. On the external environment front, soaring energy and raw material prices together with the weak yen (averaging ¥153/USD) are exerting upward pressure on procurement costs, while solid budget execution by universities and public research institutions continues to underpin revenue.
Growth Strategy
First year of the three-year plan: sustainable growth through full-scale rollout of new businesses, global strengthening, and inventory optimization
As the first-year initiative of the three-year plan, the company is working on inventory optimization and rapid shipment. In the first quarter of FY2026 (ending March 2026), merchandise and finished goods decreased by ¥119 million (from ¥1,011 million to ¥891 million), indicating that inventory reduction is progressing. This has been achieved alongside a 7.7% increase in net sales, suggesting that the effects of improved turnover are beginning to appear.
By expanding contract services such as Custom Peptide Synthesis & Antibody Production Service and proprietary products, the company aims to reduce its dependence on imported goods sales and improve gross margin. In the first quarter of FY2026 (ending March 2026), the gross margin of 34.1% was nearly maintained versus the prior-year actual of 34.2%, indicating that the product portfolio is functioning to protect gross margin levels even amid price competition.
The company is promoting the expansion of overseas sales leveraging its overseas subsidiary COSMO BIO USA, INC., and reinforcing its global strategy under the new medium-term plan. While uncertainty stemming from geopolitical risks (the situation in Ukraine and the Middle East) exists as an external risk, expanding sales channels in overseas markets contributes to diversifying revenue sources over the medium to long term.
The company is fully rolling out new businesses such as Contract Protein Manufacturing Using Egg Bioreactors and Scientist³ (Scientist Cube) to diversify its revenue sources. While the scale of their contribution to sales has not yet been disclosed, these initiatives are positioned as key measures of the three-year plan and are expected to contribute to margin improvement over the medium term.
Last updated: July 17, 2026